In terms of clinical progress, Aptevo highlighted the promising results from its mipletamig program, which demonstrated an 86% clinical benefit rate in a cohort of 28 frontline acute myeloid leukemia (AML) patients. Notably, no cytokine release syndrome was observed, suggesting a favorable safety profile. The data supports mipletamig's potential to enhance standard-of-care treatments for AML, particularly in older or unfit patients. Marvin White, President and CEO, emphasized the company's commitment to advancing its clinical programs and expanding its CD3 pipeline, which now includes trispecific drug candidates. As Aptevo transitions leadership with White moving to Executive Chair and Jeff Lamothe stepping in as CEO, the company aims to build on its momentum and continue delivering innovative therapies for cancer treatment.
2026-03-26 20:07:11
Aptevo Therapeutics Reports 2025 Financial Results and Clinical Progress with Mipletamig
Expected Stock impact: Noticeably Positive
On March 26, 2026, Aptevo Therapeutics Inc. (Nasdaq: APVO) announced its financial results for the year ended December 31, 2025, alongside a business update highlighting significant clinical advancements. The company reported a net loss of $26.0 million for 2025, compared to a loss of $24.1 million in 2024. The increase in losses was attributed to higher research and development expenses, primarily due to costs associated with the mipletamig program. Aptevo's cash and cash equivalents stood at $21.6 million at year-end, a significant increase from $8.7 million in 2024, indicating improved liquidity. The company also established a $60 million equity line facility in 2026, enhancing its financial flexibility.
In terms of clinical progress, Aptevo highlighted the promising results from its mipletamig program, which demonstrated an 86% clinical benefit rate in a cohort of 28 frontline acute myeloid leukemia (AML) patients. Notably, no cytokine release syndrome was observed, suggesting a favorable safety profile. The data supports mipletamig's potential to enhance standard-of-care treatments for AML, particularly in older or unfit patients. Marvin White, President and CEO, emphasized the company's commitment to advancing its clinical programs and expanding its CD3 pipeline, which now includes trispecific drug candidates. As Aptevo transitions leadership with White moving to Executive Chair and Jeff Lamothe stepping in as CEO, the company aims to build on its momentum and continue delivering innovative therapies for cancer treatment.
In terms of clinical progress, Aptevo highlighted the promising results from its mipletamig program, which demonstrated an 86% clinical benefit rate in a cohort of 28 frontline acute myeloid leukemia (AML) patients. Notably, no cytokine release syndrome was observed, suggesting a favorable safety profile. The data supports mipletamig's potential to enhance standard-of-care treatments for AML, particularly in older or unfit patients. Marvin White, President and CEO, emphasized the company's commitment to advancing its clinical programs and expanding its CD3 pipeline, which now includes trispecific drug candidates. As Aptevo transitions leadership with White moving to Executive Chair and Jeff Lamothe stepping in as CEO, the company aims to build on its momentum and continue delivering innovative therapies for cancer treatment.
